ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K for March 2021. The filing identifies the company as a Swiss foreign private issuer and references the year ended December 31, 2020. The filing includes a CEO letter to shareholders, consolidated IFRS financial statements, statutory financial statements, and a compensation report.
Financial metrics
The provided filing text is limited to the Form 6-K cover page and exhibit index. It does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material changes versus the prior comparable period
The provided text does not describe material changes versus the prior comparable period. Comparative information may be contained in Exhibit 99.2, but that exhibit was not included in the source text.
Guidance, outlook, risks, and unusual items
The provided text does not include management guidance, outlook commentary, risk disclosures, contingencies, or unusual items. These matters may be addressed in the CEO letter or financial statement exhibits, which were listed but not provided.
Key facts for investor verification
- Obtain and review Exhibit 99.1 for management’s business outlook and commentary.
- Review Exhibit 99.2 for consolidated IFRS revenue, operating results, cash flows, liquidity, debt, and comparative figures.
- Review Exhibit 99.3 for the statutory financial position of ADC Therapeutics SA.
- Review Exhibit 99.4 for executive compensation and related disclosures.
- Confirm whether the exhibits contain material subsequent events or changes after December 31, 2020.